Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
Quality and purity can vary significantly between sources, making pharmaceutical-grade sourcing essential for clinical use
As you adapt, the side effects will decrease
Dahlia Putrus, PA-C Dahlia, PA-C is a board-certified Physician Assistant specializing in aesthetic medicine, bringing both emergency medicine precision and an artists eye to every treatment
US$ 28.29
US$ 26.07
US$ 21.38
US$ 26.31
US$ 24.56
US$ 25.39
US$ 26.26
US$ 25.59
